Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Duning

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Journal of the American Society of Nephrology : JASN|July 18, 2015
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-UpMalte Lenders, Sima Canaan-Kühl, Johannes Krämer, et al.
Alzheimer'S Research & Therapy|October 13, 2018
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a studyPhilip Scheltens, Merja Hallikainen, Timo Grimmer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 30, 2017
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosagesJohannes Krämer, Malte Lenders, Sima Canaan-Kühl, et al.
Orphanet Journal of Rare Diseases|July 1, 2016
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry diseaseMalte Lenders, Julia B Hennermann, Christine Kurschat, et al.
Journal of the American Society of Nephrology : JASN|February 22, 2014
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switchFrank Weidemann, Johannes Krämer, Thomas Duning, et al.
Deutsches Arzteblatt International|February 24, 2022
Structured Delirium Management in the HospitalJulia Krämer, Katharina Nolte, Laura Zupanc, et al.
Neurology|July 24, 2015
Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomographyMarius Ringelstein, Philipp Albrecht, Ilka Kleffner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2017
Diagnostic criteria for Susac syndromeIlka Kleffner, Jan Dörr, Marius Ringelstein, et al.
Clinical Pharmacology and Therapeutics|March 22, 2020
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2022
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Journal of the American Society of Nephrology : JASN|July 18, 2015
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-UpMalte Lenders, Sima Canaan-Kühl, Johannes Krämer, et al.
Alzheimer'S Research & Therapy|October 13, 2018
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a studyPhilip Scheltens, Merja Hallikainen, Timo Grimmer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 30, 2017
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosagesJohannes Krämer, Malte Lenders, Sima Canaan-Kühl, et al.
Orphanet Journal of Rare Diseases|July 1, 2016
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry diseaseMalte Lenders, Julia B Hennermann, Christine Kurschat, et al.
Journal of the American Society of Nephrology : JASN|February 22, 2014
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switchFrank Weidemann, Johannes Krämer, Thomas Duning, et al.
Deutsches Arzteblatt International|February 24, 2022
Structured Delirium Management in the HospitalJulia Krämer, Katharina Nolte, Laura Zupanc, et al.
Neurology|July 24, 2015
Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomographyMarius Ringelstein, Philipp Albrecht, Ilka Kleffner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2017
Diagnostic criteria for Susac syndromeIlka Kleffner, Jan Dörr, Marius Ringelstein, et al.
Clinical Pharmacology and Therapeutics|March 22, 2020
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2022
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
Pageof 10